Patents by Inventor Michael Giannis

Michael Giannis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • THERAPEUTIC DENDRIMERS
    Publication number: 20240115716
    Abstract: Disclosed are dendrimers of formula (I): and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions comprising the dendrimer of formula (I) and methods of using the same for treating cancer.
    Type: Application
    Filed: June 14, 2023
    Publication date: April 11, 2024
    Inventors: Marianne Bernice ASHFORD, Iain GRANT, Edward John HENNESSY, William MCCOULL, Michael GIANNIS, Brian KELLY, David OWEN, John Paul SECRIST
  • Therapeutic dendrimers
    Patent number: 11717574
    Abstract: Disclosed are dendrimers of formula (I): and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions comprising the dendrimer of formula (I) and methods of using the same for treating cancer.
    Type: Grant
    Filed: November 11, 2020
    Date of Patent: August 8, 2023
    Assignee: ASTRAZENECA AB
    Inventors: Marianne Bernice Ashford, Iain Grant, Edward John Hennessy, William Mccoull, Michael Giannis, Brian Kelly, David Owen, John Paul Secrist
  • THERAPEUTIC DENDRIMERS
    Publication number: 20210060172
    Abstract: Disclosed are dendrimers of formula (I): and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions comprising the dendrimer of formula (I) and methods of using the same for treating cancer.
    Type: Application
    Filed: November 11, 2020
    Publication date: March 4, 2021
    Inventors: Marianne Bernice ASHFORD, Iain GRANT, Edward John HENNESSY, William MCCOULL, Michael GIANNIS, Brian KELLY, David OWEN, John Paul SECRIST
  • Therapeutic dendrimers
    Patent number: 10888624
    Abstract: Disclosed are dendrimers of formula (I): and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions comprising the dendrimer of formula (I) and methods of using the same for treating cancer.
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: January 12, 2021
    Assignee: ASTRAZENECA AB
    Inventors: Marianne Bernice Ashford, Iain Grant, Edward John Hennessy, William McCoull, Michael Giannis, Brian Kelly, David Owen, John Paul Secrist
  • Dendrimer-drug conjugates
    Patent number: 10730999
    Abstract: The present invention generally relates to macromolecules of dendrimer-drug conjugates. In particular, the invention relates to macromolecules comprising a pharmaceutically active agent, such as a protein or peptide, attached to a core of a dendrimer derived from branched building units, such as lysine or lysine analogues. The invention also relates to the synthesis of the dendrimers and macromolecules, and the use of such macromolecules, particularly in therapeutic applications, and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: August 4, 2020
    Assignee: Starpharma Pty Ltd
    Inventors: David James Owen, Pauline Stanislawski, Michael Giannis, Oliver Bernhard
  • THERAPEUTIC DENDRIMERS
    Publication number: 20200069810
    Abstract: Disclosed are dendrimers of formula (I): and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions comprising the dendrimer of formula (I) and methods of using the same for treating cancer.
    Type: Application
    Filed: April 5, 2019
    Publication date: March 5, 2020
    Inventors: Marianne Bernice ASHFORD, Iain GRANT, Edward John HENNESSY, William MCCOULL, Michael GIANNIS, Brian KELLY, David OWEN, John Paul SECRIST
  • Therapeutic dendrimers
    Patent number: 10314920
    Abstract: Disclosed are dendrimers of formula (I): and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions comprising the dendrimer of formula (I) and methods of using the same for treating cancer.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: June 11, 2019
    Assignee: AstraZeneca AB
    Inventors: Marianne Bernice Ashford, Iain Grant, Edward John Hennessy, William McCoull, Michael Giannis, Brian Kelly, David Owen, John Paul Secrist
  • THERAPEUTIC DENDRIMERS
    Publication number: 20180264127
    Abstract: Disclosed are dendrimers of formula (I): and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions comprising the dendrimer of formula (I) and methods of using the same for treating cancer.
    Type: Application
    Filed: February 20, 2018
    Publication date: September 20, 2018
    Inventors: Marianne Bernice ASHFORD, Iain GRANT, Edward John HENNESSY, William MCCOULL, Michael GIANNIS, Brian KELLY, David OWEN, John Paul SECRIST
  • Dendrimer-Drug Conjugates
    Publication number: 20170189543
    Abstract: The present invention generally relates to macromolecules of dendrimer-drug conjugates. In particular, the invention relates to macromolecules comprising a pharmaceutically active agent, such as a protein or peptide, attached to a core of a dendrimer derived from branched building units, such as lysine or lysine analogues. The invention also relates to the synthesis of the dendrimers and macromolecules, and the use of such macromolecules, particularly in therapeutic applications, and pharmaceutical compositions comprising them.
    Type: Application
    Filed: June 5, 2015
    Publication date: July 6, 2017
    Inventors: David James Owen, Pauline Stanislawski, Michael Giannis, Oliver Bernhard